Michael Brawer
Overview
Explore the profile of Michael Brawer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
207
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shore N, Hafron J, Langford T, Stein M, DeHart J, Brawer M, et al.
Urol Pract
. 2023 Jun;
6(4):256-261.
PMID: 37317474
Introduction: There is an unmet need for noninvasive methods to better identify patients at increased risk for clinically significant prostate cancer. SelectMDx® is a molecular urine test validated for the...
2.
Haese A, Trooskens G, Steyaert S, Hessels D, Brawer M, Vlaeminck-Guillem V, et al.
J Urol
. 2019 Apr;
202(2):256-263.
PMID: 31026217
Purpose: A 2-gene, urine based molecular test that combines mRNA biomarkers with clinical factors can risk stratify patients for clinically significant prostate cancer. To ensure the generalizability of assay results...
3.
Hartzfeld D, Berse B, Lowrance W, Dash A, Brawer M, Lawrence J, et al.
Fed Pract
. 2019 Feb;
33(Suppl 1):46S-51S.
PMID: 30766204
Genomic testing may be a vital component in the medical management of patients with complex clinical phenotypes and cancer.
4.
Canter D, Reid J, Latsis M, Variano M, Halat S, Rajamani S, et al.
Eur Urol
. 2018 Nov;
75(3):515-522.
PMID: 30391079
Background: Better prostate cancer risk stratification is necessary to inform medical management, especially for African American (AA) men, for whom outcomes are particularly uncertain. Objective: To evaluate the utility of...
5.
Lin D, Crawford E, Keane T, Evans B, Reid J, Rajamani S, et al.
Urol Oncol
. 2018 Apr;
36(6):310.e7-310.e13.
PMID: 29655620
Background: A combined clinical cell-cycle risk (CCR) score that incorporates prognostic molecular and clinical information has been recently developed and validated to improve prostate cancer mortality (PCM) risk stratification over...
6.
Morgan T, Mehra R, Tiemeny P, Wolf J, Wu S, Sangale Z, et al.
Eur Urol
. 2017 Dec;
73(5):763-769.
PMID: 29249291
Background: There is a critical need for improved prognostic discrimination in patients with renal cell carcinoma (RCC) given the increasing awareness that some patients may be managed with active surveillance,...
7.
Tosoian J, Chappidi M, Bishoff J, Freedland S, Reid J, Brawer M, et al.
BJU Int
. 2017 May;
120(6):808-814.
PMID: 28481440
Objectives: To determine the prognostic utility of the cell cycle progression (CCP) score in men with National Comprehensive Cancer Network (NCCN)-defined low-risk prostate cancer (PCa) undergoing radical prostatectomy (RP). Patients...
8.
Koch M, Cho J, Kaimakliotis H, Cheng L, Sangale Z, Brawer M, et al.
Cancer Biomark
. 2016 Jun;
17(1):83-8.
PMID: 27314296
Background: Determining the optimal treatment for biochemical recurrence (BCR) after radical prostatectomy (RP) is challenging. Objective: We evaluated the ability of CCP score (a prognostic RNA expression signature) to discriminate...
9.
Nickel J, Gorin M, Partin A, Assimos D, Brawer M, Nicolai H, et al.
Rev Urol
. 2015 Nov;
17(3):179-89.
PMID: 26543434
No abstract available.
10.
Bishoff J, Freedland S, Gerber L, Tennstedt P, Reid J, Welbourn W, et al.
J Urol
. 2014 Feb;
192(2):409-14.
PMID: 24508632
Purpose: The cell cycle progression score is associated with prostate cancer outcomes in various clinical settings. However, previous studies of men treated with radical prostatectomy evaluated cell cycle progression scores...